Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: MSNBC.com
Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despitetwo major trials last monthWhile GLP-1 drugs have become synonymous with dramatic weight loss, they’ve also becomeone of the most closely watched experimental approachesThat’s why Novo Nordisk’sannouncement last month that it discontinued two large trials“This is not what we hoped for,” Dr. Peter Johannsen, Novo Nordisk’s international medical vice president of obesity and cardiometabolic, said in an interview. “We really did expect a change.”Scientists have spent years studying how GLP-1 medications affect inflammation, metabolism and blood vessels in the brain —factors long suspected to contribute to Alzheimer’scause changes in the brain“If you look at everything that we currently understand about how the GLP-1s act in the body, all that kind of points to maybe they’ll do something in Alzheimer’s,” Wilcock said.On Wednesday, Novo Nordisk scientists presented the findings of their Pha
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- 4 stocks to watch on Thursday: NVO, PLTR, DG, PSKY [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website